60 DEGREES PHARMACEUTICALS, INC. (SXTP): Nasdaq/NYSE listing notice — 60 Degrees Pharma receives Nasdaq bid price deficiency notice; 180-day cure period

60 DEGREES PHARMACEUTICALS, INC.

Nasdaq notified SXTP that common stock failed to maintain $1.00 minimum bid price for 31 consecutive business days through Feb 27, 2024.
Company has 180 calendar days, until August 26, 2024, to regain compliance with the Bid Price Rule.
If non-compliant by Aug 26, Company may be eligible for additional 180-day period if it meets other listing standards.
Company is evaluating options; there is no immediate effect on listing of SXTP or SXTPW on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

60 DEGREES PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

n stating that for the 31 consecutive business day period between January 11, 2024 through February 27, 2024, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until August 26, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

60 DEGREES PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-017634

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.